[Psilocybin in the setting of treatment-resistant unipolar depression: A case report].

Journal: L'Encephale
Published Date: May 23, 2025

Abstract

BACKGROUND: Current antidepressants have shown certain limitations in the treatment of unipolar depression. Their long onset of action, interactions, and side effects are obstacles to achieving lasting remission of this prevalent, often chronic or recurrent, pathology. Faced with this clinical necessity, research efforts have intensified in recent years around psychedelic drugs, with a particular focus on the mental health benefits of psilocybin. To illustrate this promising approach, we present here the clinical vignette of a student living in France for whom psilocybin led to complete remission after recurrent depressive episodes and a two-year course of Escitalopram.

Authors

  • Maroussia Dumenil
    UMR 1253, iBraiN, Inserm, université de Tours, Tours, France.
  • Gabriel Cordova
    Centre de recherche sur l'inflammation, hôpital Bichat Claude-Bernard, Paris, France.
  • Wissam El-Hage
    UMR 1253, iBraiN, Inserm, université de Tours, Tours, France; Clinique psychiatrique universitaire, centre expert dépression résistante, CHRU de Tours, Tours, France. Electronic address: wissam.elhage@univ-tours.fr.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals